Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ventilator-associated pneumonia: what is new?

Jean Chastre1

  • 1Institut de Cardiologie, Hôpital Pitié-Salpêtrière, Paris, France. jean.chastre@psl.ap-hop-paris.fr

Surgical Infections
|August 10, 2006
PubMed
Summary

Prompt treatment of ventilator-associated pneumonia (VAP) is crucial for reducing mortality. A two-stage approach to antimicrobial therapy can effectively manage VAP while minimizing antibiotic overuse and resistance.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phenotypic convergence and collateral susceptibility development in Pseudomonas aeruginosa under antibiotic exposure in ICU patients.

npj antimicrobials and resistance·2026
Same author

A consensus of European experts on the definition of ventilator-associated pneumonia recurrences obtained by the Delphi method: the RECUVAP study.

Intensive care medicine·2025
Same author

Subjective and objective survival prediction in mechanically ventilated critically ill patients: a prospective cohort study.

Critical care (London, England)·2023
Same author

Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients: a randomised controlled trial.

Critical care (London, England)·2022
Same author

Bronchoscopy for diagnosis of ventilator-associated pneumonia.

Intensive care medicine·2022
Same author

Viral Ventilator-Associated Pneumonia/Hospital-Acquired Pneumonia.

Seminars in respiratory and critical care medicine·2022

Area of Science:

  • Critical Care Medicine
  • Infectious Diseases
  • Pharmacology

Background:

  • Ventilator-associated pneumonia (VAP) is the most common intensive care unit (ICU)-acquired infection.
  • Inadequate or delayed antimicrobial therapy for VAP correlates with increased mortality.
  • Effective VAP management requires balancing appropriate treatment with antibiotic stewardship to prevent resistance.

Purpose of the Study:

  • To outline a strategic approach for antimicrobial therapy in VAP.
  • To emphasize the importance of prompt and appropriate treatment initiation.
  • To discuss methods for optimizing antibiotic use in VAP management.

Main Methods:

  • Literature review of English-language studies.
  • Analysis of current practices in VAP management.
  • Synthesis of evidence regarding antimicrobial therapy strategies.

Main Results:

  • VAP antimicrobial therapy involves a two-stage process: rapid identification and empirical treatment, followed by de-escalation.
  • Empirical broad-spectrum antibiotics are recommended for potential difficult-to-treat pathogens.
  • Strategies to avoid antibiotic overuse include early discontinuation, de-escalation to monotherapy, and shortened treatment durations (7-8 days).

Conclusions:

  • A structured, two-stage antimicrobial strategy is logical for VAP management.
  • Further research is needed to optimize the implementation of this VAP treatment approach.
  • Balancing effective treatment with antibiotic stewardship remains a key challenge.

Related Experiment Videos